cas 609-71-2|| where to buy 2-Hydroxynicotinic acid

Nom du produit:2-Hydroxynicotinic acid

IUPAC Name:2-oxo-1,2-dihydropyridine-3-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)
CM178226-500g	in stock	ĽȎȎ
CM178226-1000g	in stock	ȎưȎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 609-71-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:609-71-2; Formule moléculaire:C6H5NO3; Point de fusion:-; Code SMILES:O=C1C(=CC=CN1)C(O)=O; Densité:

: Numéro de catalogue:CM178226; Poids moléculaire:139.11; Point d'ébullition:436°C at 760 mmHg; N° Mdl:MFCD01859877; Stockage:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: BNC-210; Bionomics Ltd.’s drug candidate, BNC-210 would be advanced into Phase 3 studies in Social Anxiety Disorder (SAD) after the successful End-of-Phase 2 Meeting with the U.S. FDA in September. BNC-210 has a unique action potential that depends on acetylcholine neurotransmission and allosteric modulation of α7 nAChR. It is designed to treat patients with serious central nervous system (CNS) disorders with limited side effects. BNC-210 received Fast-Track designation from the FDA for the acute treatment of SAD.